BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/5/2024 10:19:29 AM | Browse: 55 | Download: 226
 |
Received |
|
2024-03-31 07:02 |
|
Peer-Review Started |
|
2024-03-31 07:02 |
|
First Decision by Editorial Office Director |
|
2024-05-18 16:59 |
|
Return for Revision |
|
2024-05-18 16:59 |
|
Revised |
|
2024-06-12 08:58 |
|
Publication Fee Transferred |
|
2024-06-26 02:04 |
|
Second Decision by Editor |
|
2024-06-25 02:51 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-06-25 10:19 |
|
Articles in Press |
|
2024-06-25 10:19 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-07-01 07:48 |
|
Publish the Manuscript Online |
|
2024-07-05 10:19 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Small cell lung carcinoma with KIF5B-RET fusion partially responded to the 4th-line therapy with anlotinib: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rui Zhang, Yu-Ting He, Yi-Sha Liu, Hang Li and Feng Zhao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Open Funding from Meat Processing Key Laboratory of Sichuan Province |
22-R-16 |
|
| Corresponding Author |
Feng Zhao, MBBS, Doctor, Doctor, Department of Oncology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32 W. 1st Ring Road, Qingyang District, Chengdu 610072, Sichuan Province, China. zhaofengzl@med.uestc.edu.cn |
| Key Words |
KIF5B-RET fusion; Small cell lung cancer; Anlotinib; Partial response; Next-generation sequencing; Case report |
| Core Tip |
This work describes a rare case of a KIF5B-RET fusion in small cell lung cancer (SCLC) and the patient's sustained partial response to the 4th line therapy with anlotinib. The study highlights the potential of RET fusions as a promising molecular target in SCLC treatment and emphasizes the importance of next-generation sequencing for personalized therapy options. The innovative arguments include the identification of a novel fusion in SCLC and the potential for targeted therapy to enhance the survival rates of SCLC patients. |
| Publish Date |
2024-07-05 10:19 |
| Citation |
Zhang R, He YT, Liu YS, Li H, Zhao F. Small cell lung carcinoma with KIF5B-RET fusion partially responded to the 4th-line therapy with anlotinib: A case report. World J Clin Cases 2024; 12(23): 5410-5415 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i23/5410.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i23.5410 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
